RT Journal Article
SR Electronic
T1 <sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with <sup>18</sup>F-FDG
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 938
OP 943
DO 10.2967/jnumed.123.267281
VO 65
IS 6
A1 Kline, Brad
A1 Yadav, Surekha
A1 Seo, Youngho
A1 Ippisch, Robin Cumming
A1 Castillo, Jessa
A1 Aggarwal, Rahul R.
A1 Kelley, Robin Kate
A1 Behr, Spencer C.
A1 Flavell, Robert R.
A1 Lawhn-Heath, Courtney
A1 Melisko, Michelle
A1 Rugo, Hope S.
A1 Wang, Victoria
A1 Yom, Sue S.
A1 Ha, Patrick
A1 Jiang, Fei
A1 Hope, Thomas A.
YR 2024
UL http://jnm.snmjournals.org/content/65/6/938.abstract
AB Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present the first—to our knowledge—dosimetry analysis to date, and compare the agent with 18F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool). Absorbed doses were evaluated using MIM Encore and OLINDA/EXM version 1.1 using the International Commission on Radiological Protection publication 103 tissue weighting factor. Results: Forty-six patients were imaged with 68Ga-FAP-2286 PET. The highest average uptake was seen in sarcoma, cholangiocarcinoma, and colon cancer. The lowest uptake was found in lung cancer and testicular cancer. The average SUVmax was significantly higher on 68Ga-FAP-2286 PET than on 18F-FDG PET in cholangiocarcinoma (18.2 ± 6.4 vs. 9.1 ± 5.0, P = 0.007), breast cancer (11.1 ± 6.8 vs. 4.1 ± 2.2, P &lt; 0.001), colon cancer (13.8 ± 2.2 vs. 7.6 ± 1.7, P = 0.001), hepatocellular carcinoma (9.3 ± 3.5 vs. 4.7 ± 1.3, P = 0.01), head and neck cancer (11.3 ± 3.5 vs. 7.6 ± 5.5, P = 0.04), and pancreatic adenocarcinoma (7.4 ± 1.8 vs. 3.7 ± 1.0, P = 0.01). The total-body effective dose was estimated at 1.16E−02 mSv/MBq, with the greatest absorbed organ dose in the urinary bladder wall (9.98E−02 mGy/MBq). Conclusion: 68Ga-FAP-2286 biodistribution, dosimetry, and tumor uptake were similar to those of previously reported FAPI compounds. Additionally,68Ga-FAP-2286 PET had consistently higher uptake than 18F-FDG PET. These results are especially promising in the setting of small-volume disease and differentiating tumor from inflammatory uptake.